bluebird bio Reports Fourth Quarter and Full Year 2021 Financial Results, Highlights Operational Progress and Provides Corporate UpdateBusiness Wire • 03/04/22
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/15/22
Bluebird Bio: Gene Therapy Launches Could Bring Big Revenues, Providing They Meet ApprovalSeeking Alpha • 02/07/22
FDA Pushes Review Period For Bluebird bio's Neurodegenerative Disease, Thalassemia Gene TherapiesBenzinga • 01/18/22
bluebird Provides Update on FDA Review Timelines for Betibeglogene Autotemcel (beti-cel) for Beta-Thalassemia and Elivaldogene Autotemcel (eli-cel) for Cerebral Adrenoleukodystrophy (CALD)Business Wire • 01/18/22
bluebird bio to Provide Update on Program Milestones and 2022 Financial Outlook at the 40th Annual J.P. Morgan Healthcare ConferenceBusiness Wire • 01/11/22
UPDATE: Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy programMarket Watch • 12/20/21
Bluebird Bio announces partial clinical hold for patients under 18 in sickle cell gene therapy programMarket Watch • 12/20/21
bluebird bio Announces Partial Clinical Hold for Patients Under 18 in Sickle Cell Gene Therapy Clinical ProgramBusiness Wire • 12/20/21
Bluebird bio's Neurodegenerative Disease Gene Therapy Under Priority FDA Review, Despite Clinical HoldBenzinga • 12/20/21
bluebird bio Announces FDA Priority Review of Biologics License Application for eli-cel Gene Therapy for Cerebral Adrenoleukodystrophy (CALD) in Patients Without a Matched Sibling DonorBusiness Wire • 12/17/21
Bluebird (BLUE) Loses 20.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerZacks Investment Research • 12/15/21
New and Updated Data Demonstrating Sustained Treatment Response in Patients Treated in Largest Sickle Cell Gene Therapy Program To-Date Presented at ASH21 and Published in NEJMBusiness Wire • 12/12/21
New Data at ASH21, Published in NEJM Further Demonstrate beti-cel as a Potentially Curative One-Time Gene Therapy for β-thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable TI and Normal or Near-Normal Adult Hb LevelsBusiness Wire • 12/11/21